Navignostics is a precision oncology company pioneering the use of spatial single-cell proteomics to transform cancer diagnostics and treatment selection. Founded in 2022 as a spin-off from the University of Zurich’s Bodenmiller Lab, Navignostics combines highly multiplex tumor imaging with advanced data analytics to guide clinicians in identifying the most effective, personalized therapies for each cancer patient. Navignostics’ diagnostics test delivers detailed insights into tumor and immune cell composition from a single tissue section, providing a report that supports both individualized treatment decisions for patients and the development of novel targeted therapies. A recently in nature medicine published, Navignostics-backed study demonstrates that multiomics tumor profiling can drive dramatically improved outcomes for patients with advanced melanoma, particularly those with few remaining treatment options (Miglino et al., 2025). In a matched analysis of patients who had received at least three prior lines of therapy, multiomics-guided treatment, led to a median progression-free survival (PFS) of 8.34 months, compared to just 2.0 months in the matched cohort. The disease control rate (DCR) in this group was 64.7%, nearly three times higher than the 23.5% seen in non-TuPro patients. These findings suggest a strong clinical benefit of multiomics tumor profiling in late-line settings where standard diagnostic approaches often fail to guide effective treatment.